| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | Plcb; AI132408; mKIAA0581; 3110043I21Rik |
| Entrez GeneID | 18795 |
| WB Predicted band size | Calculated MW: 138 kDa; Observed MW: 138 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Rat |
| Immunogen | Recombinant protein of mouse Phospholipase C beta 1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3-4条关于CPT2抗体的参考文献示例(内容为模拟生成，非真实文献)：
1. **"Characterization of CPT2 deficiency using a novel monoclonal antibody in human skeletal muscle"**
- **作者**: Isackson, P.J. et al.
- **摘要**: 研究开发了一种特异性识别CPT2蛋白的单克隆抗体，用于Western Blot和免疫组化分析，揭示了CPT2缺陷患者肌肉组织中蛋白表达缺失与基因突变的关联。
2. **"Immunolocalization of carnitine palmitoyltransferase II (CPT2) in human liver and fibroblasts"**
- **作者**: Bonnefont, J.P. et al.
- **摘要**: 通过CPT2抗体进行免疫荧光定位，证实CPT2蛋白主要分布于线粒体内膜，为研究脂肪酸氧化障碍的细胞病理机制提供工具。
3. **"CPT2 antibody as a diagnostic marker for metabolic myopathies"**
- **作者**: Nielsen, T.L. et al.
- **摘要**: 评估CPT2抗体在肌肉活检中的诊断价值，发现其可有效区分CPT2缺乏症与其他脂质代谢疾病，提高临床诊断准确性。
4. **"Autoantibodies against CPT2 in idiopathic inflammatory myopathies"**
- **作者**: Klemm, P. & Schmidt, J.
- **摘要**: 首次报道在部分特发性炎症性肌病患者血清中检测到抗CPT2自身抗体，提示CPT2可能成为自身免疫性肌病的新靶点。
(注：以上文献为示例，实际引用需查询PubMed等数据库获取真实研究。)
Carnitine palmitoyltransferase 2 (CPT2) is a mitochondrial enzyme critical for fatty acid β-oxidation, facilitating the transport of long-chain fatty acids into mitochondria for energy production. As a key component of the carnitine shuttle system, CPT2 catalyzes the conversion of acylcarnitines back to acyl-CoA esters, enabling their entry into the metabolic pathway. Deficiencies in CPT2 function are linked to metabolic disorders, including life-threatening hepatic encephalopathy, myopathy, and hypoketotic hypoglycemia, particularly in infants.
CPT2 antibodies are essential tools in biomedical research and diagnostics, widely used to detect and quantify CPT2 protein expression in tissues or cultured cells. They aid in studying mitochondrial dysfunction, lipid metabolism disorders, and tissue-specific CPT2 distribution. Commercial CPT2 antibodies are typically monoclonal or polyclonal, validated for applications like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Researchers rely on these antibodies to investigate CPT2-related pathologies, evaluate therapeutic interventions, or assess gene expression in model organisms.
Quality validation of CPT2 antibodies is crucial, given potential cross-reactivity with homologous proteins (e.g., CPT1). Recent advances in antibody engineering have improved specificity, supporting precision in studies of metabolic diseases. Additionally, CPT2 antibodies contribute to neonatal screening programs and muscle biopsy analyses, bridging laboratory research with clinical diagnostics. Ongoing research focuses on optimizing antibody performance for emerging techniques like spatial proteomics and single-cell sequencing, further expanding their utility in metabolic disease research.
×
